European Commission Grants Conditional Marketing Authorization for Portola Pharmaceuticals' Ondexxya™ (andexanet alfa), the First and Only Antidote for the Reversal of Factor Xa Inhibitors - GlobeNewswire
European Commission Grants Conditional Marketing Authorization for Portola Pharmaceuticals' Ondexxya™ (andexanet alfa), the First and Only Antidote for the Reversal of Factor Xa Inhibitors GlobeNewswire
Major Advance in the Treatment of European Factor Xa Inhibitor Patients Hospitalized with Life-Threatening Bleeding –. – Initial Launch in Select Countries to ...
Comments
Post a Comment